'BioSimilar' drug approved to treat certain types of anemia
(HealthDay)—Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first "biosimilar" to the anemia drugs Epogen and Procrit.
May 15, 2018
0
2
(HealthDay)—Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first "biosimilar" to the anemia drugs Epogen and Procrit.
May 15, 2018
0
2
The US Supreme Court ruled Wednesday in favor of investors seeking to join a class-action lawsuit against pharmaceutical giant Amgen for downplaying safety concerns about two anemia drugs.
Feb 28, 2013
0
0
Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...
Jan 23, 2013
0
0
The U.S. Food and Drug Administration (FDA) recently recommended that clinicians be more conservative when they prescribe chronic kidney disease (CKD) patients with drugs that treat red blood cell deficiencies. But the drug ...
Jan 19, 2012
0
0
Americans' medicines are increasingly manufactured in developing countries, where oversight is lower than in the U.S., according to a new white paper by the Pew Health Group. The U.S. Food and Drug Administration (FDA) estimates ...
Jul 12, 2011
0
0